Evista 60 - Pharmaceutical Grade

Raloxifene hydrochloride, developed by Eli Lilly & Company, received FDA approval in 1997 for the treatment and prevention of osteoporosis in postmenopausal women. It is a second-generation SERM that acts as an estrogen antagonist in breast tissue while being estrogenic in bone, supporting bone density. In 2007, its indications were expanded to include reducing the risk of invasive breast cancer. Raloxifene is also explored for gynecomastia, cardiovascular disease, and prostate cancer. It has shown potential in elevating testosterone and lowering IGF-1 in men.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Evista 60 by Pharmaceutical Grade, consult with your doctor or healthcare professional.